Samy Abdel-Raouf Fahim Morad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Samy Abdel-Raouf Fahim Morad has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Mark Kester
Department of Pharmacology, University of Virginia, Charlottesville, VA, USA
10 shared publicationsJonathan C. Levin
6 shared publicationsMyles C. Cabot
Department of Biochemistry and Molecular Biology, East Carolina University, Brody School of Medicine, Greenville, NC, USA
5 shared publications- Myles C. Cabot
East Carolina Diabetes and Obesity Institute, East Carolina University, Greenville, NC 27858, USA
5 shared publications - Brian M. Barth
Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham NH 03824 USA
4 shared publications David J. Feith
Department of Medicine, University of Virginia, Charlottesville, VA, USA
4 shared publications
Latest Publications
- 12 November 2026
- Published by Elsevier in Tissue and Cell
- Vol. 105, 104107
Gastroprotective effects of a polyphenol-enriched fraction from pulicaria undulata against indomethacin-induced gastric ulcer in rats
- 12 November 2026
- Published by Elsevier in Tissue and Cell
- Vol. 105, 104107
Gastroprotective effects of a polyphenol-enriched fraction from pulicaria undulata against indomethacin-induced gastric ulcer in rats
- 4 July 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 97 (10) , 2763-2770
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress
Chloroquine (CQ) and hydroxychloroquine (HCQ) are classical antimalarial drugs, and recently have been used for other applications including coronavirus disease 2019 (COVID-19). Although they are considered safe, cardiomyopathy may associate CQ and HCQ applications particularly at overdoses. The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart. For this purpose, a mouse model of CQ (0.5 up to 2.5 g/kg)/HCQ (1 up to 2 g/kg) toxicity was used, and the effect of vinpocetine was evaluated by survival, biochemical, as well as histopathological analyses. Survival analysis revealed that CQ and HCQ caused dose-dependent lethality, which was prevented by co-treatment with vinpocetine (100 mg/kg, oral or intraperitoneal). To gain deeper understanding, a dose of 1 g/kg CQ—which did not cause death within the first 24 h after administration—was applied with and without vinpocetine administration (100 mg/kg, intraperitoneal). The CQ vehicle group showed marked cardiotoxicity as evidenced by significant alterations of blood biomarkers including troponione-1, creatine phosphokinase (CPK), creatine kinase-myocardial band (CK-MB), ferritin, and potassium levels. This was confirmed at the tissue level by massive alteration of the heart tissue morphology and coincided with massive oxidative stress. Interestingly, co-administration of vinpocetine strongly ameliorated CQ-induced alterations and restored the antioxidant-defense system of the heart. These data suggest that vinpocetine could be used as an adjuvant therapy together with CQ/HCQ applications.
- 4 July 2023
- Published by Springer Nature in Archives of Toxicology
- Vol. 97 (10) , 2763-2770
Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress
Chloroquine (CQ) and hydroxychloroquine (HCQ) are classical antimalarial drugs, and recently have been used for other applications including coronavirus disease 2019 (COVID-19). Although they are considered safe, cardiomyopathy may associate CQ and HCQ applications particularly at overdoses. The goal of the present study was to evaluate the potential protective effect of the nootropic agent vinpocetine against CQ and HCQ adverse effects with a specific focus on the heart. For this purpose, a mouse model of CQ (0.5 up to 2.5 g/kg)/HCQ (1 up to 2 g/kg) toxicity was used, and the effect of vinpocetine was evaluated by survival, biochemical, as well as histopathological analyses. Survival analysis revealed that CQ and HCQ caused dose-dependent lethality, which was prevented by co-treatment with vinpocetine (100 mg/kg, oral or intraperitoneal). To gain deeper understanding, a dose of 1 g/kg CQ—which did not cause death within the first 24 h after administration—was applied with and without vinpocetine administration (100 mg/kg, intraperitoneal). The CQ vehicle group showed marked cardiotoxicity as evidenced by significant alterations of blood biomarkers including troponione-1, creatine phosphokinase (CPK), creatine kinase-myocardial band (CK-MB), ferritin, and potassium levels. This was confirmed at the tissue level by massive alteration of the heart tissue morphology and coincided with massive oxidative stress. Interestingly, co-administration of vinpocetine strongly ameliorated CQ-induced alterations and restored the antioxidant-defense system of the heart. These data suggest that vinpocetine could be used as an adjuvant therapy together with CQ/HCQ applications.
- Open Access
- 26 March 2023
- Published by Egyptian Knowledge Bank in Svu-International Journal of Veterinary Sciences
- Vol. 6 (1) , 31-45
Mitigation of Diclofenac Sodium–Induced Hepatic Injury and Enteropathy in Rats by Vanillin
This study aimed to evaluate the potential protective effects of Vanillin (VA) against Diclofenac sodium (DFNa)-induced liver toxicity and enteropathy. A total of sixty male rats were divided into six groups; a control group received only saline, a DFNa-group received DFNa (9 mg/kg), 3rd, 4th, and 5th groups received DFNa along with escalated doses of VA (50, 100, 200 mg/kg). After five days of treatment, blood and tissue samples were collected for biochemical and histopathological analysis. According to our findings, administration of DFNa led to a substantial decrease in the final body weight and a considerable deterioration of hematologic parameters. Regarding biochemically, DFNa-induced a significant elevation in liver enzyme activities with a significant decrease in total protein and albumin levels, indicating liver intoxication. VA maintained normalized body weight and prevented DFNa-induced adverse effects on hematologic and liver parameters.Additionally, histopathological examinations revealed that DFNa showed perivascular inflammation and cellular infiltration, along with congestion and dilation of the central vein and induction of both types of cell death (necrosis and apoptosis). In the intestinal sections, DFNa resulted in necrotic enteritis, desquamation, and sloughing of the mucosa, as well as considerable congestion and dilation of the blood vessels with prominent submucosal edema. It is intriguing to note that the VA-treated animals demonstrated a significant protective effect against the deleterious effects of the DFNa on the liver and intestine. As a result of our study, VA could be used as an adjuvant agent as part of various regimens containing DFNa.
- 26 March 2023
- Published by Egyptian Knowledge Bank in Svu-International Journal of Veterinary Sciences
- Vol. 6 (1) , 31-45
Open AccessMitigation of Diclofenac Sodium–Induced Hepatic Injury and Enteropathy in Rats by Vanillin
This study aimed to evaluate the potential protective effects of Vanillin (VA) against Diclofenac sodium (DFNa)-induced liver toxicity and enteropathy. A total of sixty male rats were divided into six groups; a control group received only saline, a DFNa-group received DFNa (9 mg/kg), 3rd, 4th, and 5th groups received DFNa along with escalated doses of VA (50, 100, 200 mg/kg). After five days of treatment, blood and tissue samples were collected for biochemical and histopathological analysis. According to our findings, administration of DFNa led to a substantial decrease in the final body weight and a considerable deterioration of hematologic parameters. Regarding biochemically, DFNa-induced a significant elevation in liver enzyme activities with a significant decrease in total protein and albumin levels, indicating liver intoxication. VA maintained normalized body weight and prevented DFNa-induced adverse effects on hematologic and liver parameters.Additionally, histopathological examinations revealed that DFNa showed perivascular inflammation and cellular infiltration, along with congestion and dilation of the central vein and induction of both types of cell death (necrosis and apoptosis). In the intestinal sections, DFNa resulted in necrotic enteritis, desquamation, and sloughing of the mucosa, as well as considerable congestion and dilation of the blood vessels with prominent submucosal edema. It is intriguing to note that the VA-treated animals demonstrated a significant protective effect against the deleterious effects of the DFNa on the liver and intestine. As a result of our study, VA could be used as an adjuvant agent as part of various regimens containing DFNa.
- Open Access
- 4 March 2021
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 20, 550-561
Vinpocetine-based therapy is an attractive strategy against oxidative stress-induced hepatotoxicity in vitro by targeting Nrf2/HO-1 pathway
Vinpocetine (Vin), a synthetic-derivative of the Vinca alkaloid- Vincamine, has been reported to possess a variety of health benefits. We herein investigated the critical role of nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant response in the protection of Vin against H2O2 and paracetamol (APAP)-induced liver toxicity. For this purpose, a normal human hepatic cell line (L02 cells) was incubated with cytotoxic concentrations of H2O2 or APAP in the presence or absence of Vin. To evaluate the responses, MTS Cell Viability assay, immunoblotting, biochemical assays, and molecular docking approach were used. Viability analysis showed that treatment of L02 cells with Vin prevented the cytotoxicity induced by H2O2 and APAP. It was evidenced by the fact that Vin dumped H2O2 and APAP cytotoxicity and reactive oxygen species (ROS) generation. The immunoblotting analysis shows that Vin increased Nrf2 expression along with the expression of target protein, heme oxygenase-1 (HO-1), and increased intracellular glutathione (GSH) level. Interestingly, we found that Vin could enhance the thermal stability of Keap1, which indicated the potential interaction between Vin and Keap1. Furthermore, molecular docking revealed that Vin possibly competed with Nrf2 for Keap1-binding site, with hydrogen and stearic interactions. Collectively, Vin effectively protects against H2O2 and APAP -induced hepatotoxicity via executing Nrf2-mediated antioxidative signaling pathway. Meanwhile, Vin interrupts protein-protein interaction between Keap1 and Nrf2 which might also contribute to decrease Nrf2 degradation and stabilize protein expression. Thus, Vin-based adjuvant therapy may represent a smart drug regimen to mitigate drug-induced oxidative stress and liver injuries.
- 4 March 2021
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 20, 550-561
Open AccessVinpocetine-based therapy is an attractive strategy against oxidative stress-induced hepatotoxicity in vitro by targeting Nrf2/HO-1 pathway
Vinpocetine (Vin), a synthetic-derivative of the Vinca alkaloid- Vincamine, has been reported to possess a variety of health benefits. We herein investigated the critical role of nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant response in the protection of Vin against H2O2 and paracetamol (APAP)-induced liver toxicity. For this purpose, a normal human hepatic cell line (L02 cells) was incubated with cytotoxic concentrations of H2O2 or APAP in the presence or absence of Vin. To evaluate the responses, MTS Cell Viability assay, immunoblotting, biochemical assays, and molecular docking approach were used. Viability analysis showed that treatment of L02 cells with Vin prevented the cytotoxicity induced by H2O2 and APAP. It was evidenced by the fact that Vin dumped H2O2 and APAP cytotoxicity and reactive oxygen species (ROS) generation. The immunoblotting analysis shows that Vin increased Nrf2 expression along with the expression of target protein, heme oxygenase-1 (HO-1), and increased intracellular glutathione (GSH) level. Interestingly, we found that Vin could enhance the thermal stability of Keap1, which indicated the potential interaction between Vin and Keap1. Furthermore, molecular docking revealed that Vin possibly competed with Nrf2 for Keap1-binding site, with hydrogen and stearic interactions. Collectively, Vin effectively protects against H2O2 and APAP -induced hepatotoxicity via executing Nrf2-mediated antioxidative signaling pathway. Meanwhile, Vin interrupts protein-protein interaction between Keap1 and Nrf2 which might also contribute to decrease Nrf2 degradation and stabilize protein expression. Thus, Vin-based adjuvant therapy may represent a smart drug regimen to mitigate drug-induced oxidative stress and liver injuries.
- Open Access
- 4 November 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (50) , 83208-83222
Acid ceramidase is upregulated in AML and represents a novel therapeutic target
Acid ceramidase is upregulated in AML and represents a novel therapeutic target Acid ceramidase is upregulated in AML and represents a novel therapeutic target
- 4 November 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (50) , 83208-83222
Open AccessAcid ceramidase is upregulated in AML and represents a novel therapeutic target
Acid ceramidase is upregulated in AML and represents a novel therapeutic target Acid ceramidase is upregulated in AML and represents a novel therapeutic target
- Open Access
- 1 July 2016
- Published by Elsevier in Journal of Lipid Research
- Vol. 57 (7) , 1231-1242
Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia
- 1 July 2016
- Published by Elsevier in Journal of Lipid Research
- Vol. 57 (7) , 1231-1242
Open AccessCeramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia
- 1 July 2016
- Published by Elsevier in Cancer Letters
- Vol. 376 (2) , 199-204
Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells
- 1 July 2016
- Published by Elsevier in Cancer Letters
- Vol. 376 (2) , 199-204
Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells
- 1 October 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (10) , 1071-1078
Dynamics of ceramide generation and metabolism in response to fenretinide – Diversity within and among leukemia
- 1 October 2015
- Published by Elsevier in Leukemia Research
- Vol. 39 (10) , 1071-1078
Dynamics of ceramide generation and metabolism in response to fenretinide – Diversity within and among leukemia
- 1 September 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1851 (9) , 1134-1145
Tamoxifen regulation of sphingolipid metabolism—Therapeutic implications
- 1 September 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1851 (9) , 1134-1145
Tamoxifen regulation of sphingolipid metabolism—Therapeutic implications